Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early Carvedilol Addition to Terlipressin in Acute Variceal Bleed
NCT05699824Unknown
- Sponsor
- Institute of Liver and Biliary Sciences
- Start
- Jul 2023
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of carvedilol in Esophageal variceal hemorrhage (EVH) (2 arms), sponsored by Institute of Liver and Biliary Sciences. Primary endpoint: Hemodynamic response (HVPG reduction of ≥20% from baseline or absolute reduction of HVPG <= 12 mmHg) at Day 5. Status: unknown.
02
Drugs
carvedilol
03
Conditions
Esophageal variceal hemorrhage (EVH)
Beyond the preview
Go deeper on NCT05699824.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05699824.